Temporal and Spatial Gait Parameters of Children Undergoing Treatment for and Surviving Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Cases will be identified and referred by the primary oncologist or by the Childhood Cancer
Survivorship team. When a possible subject has been identified they will be contacted via
telephone or during a routine clinic visit to determine their interest in the study. Two
hundred subjects will be recruited for participation with the goal of 5-10 subjects at each
of the 14 times points across the treatment protocol and survivorship. These time points to
include: at diagnosis, the start of consolidation therapy, the start of interim maintenance
therapy, the start of delayed intensification therapy, Day 29 of delayed intensification
therapy, the start of interim maintenance II therapy (if applicable), Day 1 of cycle 1,3,5
of maintenance therapy, end of therapy, and 1, 3, 5, and 10 years off therapy ( +/-1 year).
Clinical data will be collected from the medical record, roadmaps documenting
cancer-directed therapy, direct patient interview and examination by the physical therapist
during the study evaluation. Clinical data will include: Date of birth (to calculate age at
diagnosis and current age); Gender; Race and Ethnicity; Primary cancer diagnosis; Date of
Primary Cancer Diagnosis; Chemotherapeutic agents received (agent name, cumulative dose and
date received); Radiation therapy (date received, site radiated, and dose delivered); Any
other clinical conditions affecting musculoskeletal performance; Dates of previous PT; Pain
score at the time of study participation. Height, weight, shoe size and leg length will be
collected at time of study participation.
Subjects will complete a self report of the PedsQLâ„¢ Generic Core Scale and the parents will
complete the parental report.
Observation gait assessment will include hopping on one foot, running and walking 30' and
ascending/descending stairs.
Temporal spatial gait parameters will be recorded on the GaitRite mat
Observational
Time Perspective: Cross-Sectional
Susan Lindemulde, MD, MCR
Study Director
Oregon Health and Science University
United States: Institutional Review Board
OregonHSU
NCT01565447
December 2011
March 2013
Name | Location |
---|---|
Doernbecher Children Hospital | Portland, Oregon 97239 |